Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Illidge

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Blood Advances|September 3, 2020
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaArne Kolstad, Tim Illidge, Nils Bolstad, et al.
The Lancet. Oncology|March 5, 2026
Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapyAntonio Angrisani, Youlia Kirova, Azadeh Abravan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2018
Clinical Development of Novel Drug-Radiotherapy CombinationsSaif S Ahmad, Marka R Crittenden, Phuoc T Tran, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology GroupLouis S Constine, Joachim Yahalom, Andrea K Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trialChristina A Meyers, Jennifer A Smith, Andrea Bezjak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2022
Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal CancerJames M Price, Hitesh B Mistry, Guy Betts, et al.
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Lancet (London, England)|December 8, 2018
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven Horwitz, Owen A O'Connor, Barbara Pro, et al.
Nature Reviews. Clinical Oncology|June 2, 2016
Clinical development of new drug-radiotherapy combinationsRicky A Sharma, Ruth Plummer, Julie K Stock, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Blood Advances|September 3, 2020
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaArne Kolstad, Tim Illidge, Nils Bolstad, et al.
The Lancet. Oncology|March 5, 2026
Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapyAntonio Angrisani, Youlia Kirova, Azadeh Abravan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2018
Clinical Development of Novel Drug-Radiotherapy CombinationsSaif S Ahmad, Marka R Crittenden, Phuoc T Tran, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology GroupLouis S Constine, Joachim Yahalom, Andrea K Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trialChristina A Meyers, Jennifer A Smith, Andrea Bezjak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2022
Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal CancerJames M Price, Hitesh B Mistry, Guy Betts, et al.
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Lancet (London, England)|December 8, 2018
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven Horwitz, Owen A O'Connor, Barbara Pro, et al.
Nature Reviews. Clinical Oncology|June 2, 2016
Clinical development of new drug-radiotherapy combinationsRicky A Sharma, Ruth Plummer, Julie K Stock, et al.
Pageof 7